Company Overview and News

to your dashboard

Headline News

Acrux sees growth in sales of testosterone solution

This is a 33% increase in sales compared to US$29.3 million for the previous quarter to 30 June, 2016. Acrux shares were last trading at $0.355, up 6% intraday. Axiron is an underarm testosterone solution used to treat adult males who have low or no testosterone due to certain medical conditions. Acrux has developed Axiron and licensed it to Eli Lilly, receiving royalty payments on the basis of sales.

Patent Dispute Eli Lilly And Acrux: Update And Opportunity?

2016-08-24 seekingalpha
Yesterday I wrote about bad news for Eli Lilly (NYSE:LLY) and Acrux (ASX:ACR) (OTCPK:ARUXF) for their testosterone replacement therapy. The US District Court for the Southern District of Indiana declared the core protective patents for Axiron, delivery of testosterone through the armpit, to be invalid.

Patent Dispute Off The Rails For Eli Lilly And Acrux

2016-08-23 seekingalpha
Biotech is full of risk and nowhere is that more apparent than in the area of intellectual property protection. Patents define the value of blockbuster drugs, but they only offer protection if they survive challenge.

Acrux presents at BioTrinity


Acrux Appendix 4D - December 2015


Launch of Lenzetto


Appendix 3B


2015 AGM Presentation and Script


2015 AGM Results of Meeting